Αρχική World News Ovarian, bowel and non-Hodgkin’s lymphoma treatments approved for NHS use in Scotland

Ovarian, bowel and non-Hodgkin’s lymphoma treatments approved for NHS use in Scotland

Ovarian cancer micrograph

Ovarian, bowel and non-Hodgkin’s lymphoma treatments approved for NHS use in Scotland

Three new treatment options will be made available for patients in Scotland living with advanced ovarian cancer, bowel cancer and a rare form of non-Hodgkin’s lymphoma.

The latest batch of drug decisions from The Scottish Medicines Consortium (SMC) includes the approval of olaparib, nivolumab and ibrutinib for use on the NHS in Scotland.

David Ferguson, public affairs manager for Cancer Research UK in Scotland hopes the decisions will give patients facing these advanced forms of cancer “better options for treatment and more memories with the people they love.”

Targeted cancer drug made available for advanced ovarian cancer

Olaparib (Lynparza) is a type of targeted cancer treatment that blocks an enzyme called PARP from working. Without PARP, it’s more difficult for cancer cells to repair, making them more likely to die.

In a phase 3 study, olaparib was used in combination with bevacizumab to prolong the effects of initial treatment for people with advanced ovarian cancer. The SMC decision declared that olaparib plus bevacizumab gave patients longer without their cancer growing, compared to a placebo plus bevacizumab.

The treatment will be offered to adults with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer, who have already been treated with chemotherapy and bevacizumab.

It will only be an option if someone’s cancer has genetic changes that prevent cells from repair DNA damage – such as a fault in BRCA1 and BRCA2 genes, or genomic instability.

Ferguson said: “Cancer Research UK played a leading role in the first clinical trials for olaparib, which led to it being used routinely to treat ovarian cancer in patients who have the BRCA1 and BRCA2 gene faults.

“Olaparib is now a well-established treatment option for ovarian cancer and today’s decision reaffirms that position for advanced ovarian cancer.”

Immunotherapy combo approved for people with bowel cancer

In a second decision, the SMC approved an immunotherapy combo for adults with bowel cancer that has spread to other parts of the body.

The new combination of nivolumab (Opvido) and ilipimumab will be offered to people whose cancers can be described as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) due to generic changes in the cells.

Right now, there’s limited data on whether the combination can increase survival compared with current treatments like chemotherapy. But results from a phase 2 clinical trial found that by the end of the trial, 65% of patients’ cancers responded to the treatment.

Patients reported an improved quality of life undergoing this treatment compared to chemotherapy, with fewer side effects and greater hope for potentially added months and years of life.

Current NHS treatment options for advanced bowel cancer are known to be extremely limited. “It’s great news for patients that nivolumab has been approved for further use in NHS Scotland,” Ferguson said.

“Nivolumab provides a more targeted approach to treating cancer, by helping the immune system to attack tumours. Studies in metastatic colorectal cancer have found that it can help some patients live longer, as well as producing fewer side effects than other treatments.”

A new treatment option for patients with a rare type of non-Hodgkin’s lymphoma

In the final SMC cancer decision of the month, drug that blocks cancer from growing, called ibrutinib (Imbruvica) has been accepted for use with patients diagnosed with Waldenström’s macroglobulinaemia (WM).

The drug will provide a vital new option for patients who’ve already had at least one cancer treatment – which tends to be chemotherapy in combination with immunotherapy – or people who are unable to take this combination.

Right now, the only available option for people at this stage is a combination of ibrutinib plus another drug called rituximab. A combo that’s not suitable for everyone.

Having the option to take ibrutinib by itself represents a “major step change” for those diagnosed with WM. And, as an oral treatment, it reduces the need for frequent hospital visits.

Ferguson added the treatment has “shown great promise in clinical trials with patients whose cancer has come back after previous treatment, helping to keep cancer at bay for longer.”

All 3 decisions apply to NHS Scotland only, with England, Wales and Northern Ireland having a separate process for reviewing treatments.

More on this topic

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...

Cancer in My Community: Improving Access to Palliative Care in Indonesia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...

Should CAR T Cells Be Used Earlier in People with Non-Hodgkin Lymphoma?

January 13, 2022, by NCI Staff Several approved CAR T-cell therapies work by binding to the CD19 antigen on cancer cells and killing them. Credit: Adapted...